Nutrients from the food that you eat passes to your breast milk. Its good idea to take healthy diet while breastfeeding. You may need to consume more calories per day to support healthy body system. Some time it gets necessary take medicine while you are breastfeeding and as other food items passes into breast milk, medicine passes as well hence it becomes obvious to understand its effects while breastfeeding. We have analyzed many medications and in this sheet we will present some fact and known information associated with Reno-60 | Diatrizoate Meglumine Injection while breast-feeding.
What is Reno-60 | Diatrizoate Meglumine Injection used for?
Reno-60 is indicated in excretion urography (by direct I.V. or drip infusion); cerebral angiography; peripheral arteriography; venography; operative, T-tube, or percutaneous transhepatic cholangiography; splenoportography; arthrography; and discography. Computed Tomography Reno-60 (Diatrizoate Meglumine Injection USP 60%) is also indicated for radiographic contrast enhancement in computed tomography (CT) of the brain and body. Contrast enhancement may be advantageous in delineating or ruling out disease in suspicious areas which may otherwise not have been satisfactorily visualized. Brain Tumors Reno-60 may be useful to demonstrate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas; ependymomas; medulloblastomas; meningiomas; neuromas; pinealomas; pituitary adenomas; craniopharyngiomas; germinomas; and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In cases where lesions have calcified, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. Non-Neoplastic Conditions of The Brain The use of Reno-60 may be beneficial in the enhancement of images of lesions not due to neoplasms. Cerebral infarctions of recent onset may be better visualized with the contrast enhancement, while some infarctions are obscured if a contrast medium is used. The use of Reno-60 (Diatrizoate Meglumine Injection USP 60%) improved the contrast enhancement in approximately 60 percent of cerebral infarctions studied from one week to four weeks from the onset of symptoms. Sites of active infection also will produce contrast enhancement following contrast medium administration. Arteriovenous malformations and aneurysms will show contrast enhancement. In the case of these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast medium administration may be helpful in ruling out the possibility of associated arteriovenous malformation. The opacification of the inferior vermis following contrast medium administration has resulted in false-positive diagnoses in a number of normal studies. Body Scanning Reno-60 (Diatrizoate Meglumine Injection USP 60%) may be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with Reno-60 may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g., tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60-90 seconds after bolus administration of the contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when pre-contrast and enhanced scans are compared; the non-perfused mass shows unchanged X-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings.
What are the risk associated with Reno-60 | Diatrizoate Meglumine Injection usage while breastfeeding? What precautions shall I take while using it in breastfeeding?
Diatrizoate meglumine is the only one ingredient used in manufacturing of Reno-60 | Diatrizoate Meglumine Injection, Which makes it easier to analyze its effect in breastfeeding. As per our analysis of Diatrizoate meglumine it is safe to use Reno-60 | Diatrizoate Meglumine Injection while lactating. We suggest you to check further details below about Diatrizoate meglumine usage in breastfeeding.
Reno-60 | Diatrizoate Meglumine Injection Breastfeeding Analsys
Diatrizoate meglumine while Breastfeeding Safe
CAS Number: 131-49-7
The X-ray contrast media that contain Amidotryzoic acid, Meglumine and Sodium have a content of Iodine from 47% to 62%.Amidotryzoate excretion into breast milk is nil (Fitzjohn, 1982) or in clinically non-significant amount (Texier, 1983: <0.1% of maternal dose) and there have been no problems in infants whose mothers were on this medication. The various Iodinated contrast media for imaging examinations (X-rays, CT scans) are considered compatible with breastfeeding since they are rapidly eliminated with little or no release of iodine, not metabolized and virtually not absorbed when taken by mouth. They are structurally very similar to each other, and some of them have shown no or minimal excretion in the breast milk. Given a low lipoid solubility of the iodinated contrast media, less than 1% of the dose administered to the mother has been found to in the milk.Due to their low oral bioavailability, intestinal absorption is less than 1% of the dose that would be swallowed by the infant.The maximum that is finally got by the baby is less than 0.01% of the maternal dose, which represents less than 1% of the dose administered to an infant who undergoes a radiological contrast examination. Most Scientific Societies of Radiology have agreed that after a radiological iodinated contrast examination is not necessary a temporary weaning of the baby. American Academy of Pediatrics classifies it as usually compatible with breastfeeding medication.WHO List of Essential Medicines 2002 states it is compatible with breastfeeding.
I am nursing mother and I have already used Reno-60 | Diatrizoate Meglumine Injection, what should I do?
It is always a good idea to keep your healthcare provider or doctor informed about your drug usage during pregnancy and breastfeeding but if you have not informed your doctor about Reno-60 | Diatrizoate Meglumine Injection and have used it then do not panic as Reno-60 | Diatrizoate Meglumine Injection is mostly safe in breastfeeding and should not cause any harm to your baby.
My health care provider has asked me to use Reno-60 | Diatrizoate Meglumine Injection, what to do?
Usage of Reno-60 | Diatrizoate Meglumine Injection is safe for nursing mothers and baby, No worries.
If I am using Reno-60 | Diatrizoate Meglumine Injection, will my baby need extra monitoring?
Who can I talk to if I have questions about usage of Reno-60 | Diatrizoate Meglumine Injection in breastfeeding?
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week